They measured the levels of C-peptide, a direct indicator of endogenous insulin production, and postulated that hyperglycemia in patients with critical COVID-19 was due to the development of IR and not to a deficiency of pancreatic beta cells. The gene discussed is INS; the disease is Hyperglycemia.